|
|
|
LifeScienceHistory.com - Check us out on Instagram
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Apollo Endosurgery, Inc.
| | | Phone: | (858) 678-0800 | Fax: | (858) 678-0900 | Year Established: | 1997 | Ticker: | APEN | Exchange: | NASDAQ | Main Contact: | Stefanie Cavanaugh, CFO | | Other Contacts: | Charlie Dean, VP, R&D and Corporate Development Laura LeBoeuf, VP, Quality, Regulatory, and Clinical Affairs Bret Schwartzhoff, VP, US Sales & Marketing Christopher J. Gostout, MD, CMO Todd Newton, CEO Charles Tribié, Executive VP, Operations Dennis L. McWilliams, President & CCO
| | Company Description | Apollo Endosurgery, formerly Lpath, is the category leader in lipid-targeted therapeutics. The company's ImmuneY2™ drug-discovery engine has the unique ability to generate therapeutic antibodies that bind to and inhibit lipids that contribute to disease. The company has developed four drug candidates, two of which—iSONEP for wet AMD and ASONEP for cancer—are currently being investigated in Phase 2 trials. The other candidates are an anti-LPA antibody, Lpathomab, for neuropathic pain and an anti-leukotriene antibody, Altepan, which is being studied in models of inflammatory bowel disease, respiratory disease and inflammation.
On Dec. 28, 2016, Apollo Endosurgery announced that it had completed its merger transaction with Lpath. With the completion of the merger, Lpath was renamed Apollo Endosurgery, Inc. and will began trading on the NASDAQ Global Market under the symbol ‘APEN’ on Dec. 30, 2016. | |
|
|
|
|
|